Description
Adakveo (crizanlizumab) is a prescription biologic medication manufactured by Novartis Pharmaceuticals Corporation. It acts as a P-selectin blocker to help manage certain conditions. Administered intravenously as an injection at 10 mg/mL strength. This information was generated using AI and is provided for informational and research purposes only.
Resources
| Name | Format | Description | Link |
|---|---|---|---|
| Crizanlizumab | HTML | Access the FDA dataset for Crizanlizumab — ANDA 761128 submitted by Mylan Institutional LLC | Open resource |